Forget cash ISAs! At 4.4% dividend yield, I’ll buy this FTSE 100 stock

GSK is delivering a 4.4% dividend yield. That’s more than double what you would get from a cash ISA.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has a market capitalisation of over £90 billion, making it one of the 10 largest companies listed on the London Stock Exchange. Since its founding in 2000, from the merger of Glaxo Wellcome and SmithKline Beecham, the company has been returning real value to its shareholders.

GSK has been regularly paying dividends for years. In fact, its annual payment has consistently grown at a compounded annual growth rate of roughly 3.4% over the past 10 years. Last year, the pharmaceutical giant yielded 4.4% in dividends. I believe these characteristics make it ideal for income investors.

In comparison, a good easy-access cash ISA may give you returns of 2%. I don’t know about you, but I know where I would invest my money.

A strong business base

GSK’s business base is strong. Consider the fact that the company has succeeded in diversifying its revenue sources over the years. Apart from pharmaceuticals, GSK is into vaccines and healthcare consumer products, too.

Moreover, what is interesting is the huge commitment that the company has been showing towards research and development (R&D). In fact, currently it is reinvesting much of its cash flow into that. GSK spends close to £4 billion on R&D every year to remain relevant in the industry and develop a competitive edge.

Consequently, if there is a pharmaceutical company that will keep its place in the coming years, I believe it is GSK.

Investment in GSK is for the long haul

GSK has found itself in troubled waters in recent years. For the past five years, earnings per share (EPS) have been rapidly falling. The company has been investing heavily in R&D to update its pipeline of drugs.

Last year the stock price delivered almost 30% in return. Its R&D investments are for the intermediate to long term, so only patient investors will gain I believe.

Why I’m a buyer

GSK is a solid income stock. The drug company currently has a stunning 4.4% dividend yield. For years its annual payout has been roughly 61% and as much as 89%. Hence, apart from its declining EPS concern, GSK easily makes my watchlist.

But what about the declining EPS? The first cause is increasing competition. For example, in 2019 GSK had its Advair – a bronchodilator used to prevent symptoms of asthma and chronic obstructive pulmonary disease – challenged by the approval of a generic competitor in the U.S.

Next is its heavy investment in building its products portfolio. In December 2018, for instance, it started the acquisition of Tesaro, an oncology-focused pharmaceutical firm, for $5.1 billion.

Apart from these, the past years have actually been good for GSK. Therefore, the company’s falling EPS should not be a concern at all. And 4.4% is a lot better than 2%, don’t you think?

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Pi De Jonge has no position in any of the shares mentioned but will be opening long positions in the future. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »